SANOFI-AVENTIS (EPA:SAN) ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
Transparency directive : regulatory news
19/09/2021 17:30